{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:37:06Z","timestamp":1768639026338,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.otc.2021.05.004","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T01:31:28Z","timestamp":1623375088000},"page":"789-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders"],"prefix":"10.1016","volume":"54","author":[{"given":"Scott","family":"Raskin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Bornhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/neuros\/nyx492","article-title":"Head and Neck: Skull Base Imaging","volume":"82","author":"Hudgins","year":"2018","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.rpor.2014.12.001","article-title":"Historical development of the treatment of skull base tumours","volume":"21","author":"Mazzoni","year":"2016","journal-title":"Rep Pract Oncol Radiother"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11060-020-03637-y","article-title":"Management considerations for malignant tumors of the skull base","volume":"150","author":"DeMonte","year":"2020","journal-title":"J\u00a0Neurooncol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.004_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00106-018-0508-3","article-title":"[Complications of anterior skull base surgery]","volume":"66","author":"Wagenmann","year":"2018","journal-title":"HNO"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib5","first-page":"20","article-title":"Petroclival meningiomas: surgical experience in 109 cases","volume":"84","author":"Couldwell","year":"1996","journal-title":"J\u00a0Neurosurg"},{"issue":"Suppl","key":"10.1016\/j.otc.2021.05.004_bib6","first-page":"160","article-title":"Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate","volume":"121","author":"Seferis","year":"2014","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.otc.2021.05.004_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/TCRM.S50526","article-title":"Novel targeted therapies in chordoma: an update","volume":"11","author":"Di Maio","year":"2015","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.otc.2021.05.004_bib8","doi-asserted-by":"crossref","first-page":"7227","DOI":"10.2147\/OTT.S219056","article-title":"Therapies targeting the signal pathways of pheochromocytoma and paraganglioma","volume":"12","author":"Liu","year":"2019","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib9","doi-asserted-by":"crossref","first-page":"CNS50","DOI":"10.2217\/cns-2019-0019","article-title":"Clinical response to pazopanib in a patient with endolymphatic sac tumor not associated with von Hippel-Lindau syndrome","volume":"9","author":"Nelson","year":"2020","journal-title":"CNS Oncol"},{"key":"10.1016\/j.otc.2021.05.004_bib10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fonc.2019.00030","article-title":"Molecular Targeted Therapy in the Treatment of Chordoma: A Systematic Review","volume":"9","author":"Meng","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J\u00a0Neurooncol"},{"issue":"9679","key":"10.1016\/j.otc.2021.05.004_bib12","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","article-title":"An update on the CNS manifestations of neurofibromatosis type 2","volume":"139","author":"Coy","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib15","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/cancers12040835","article-title":"Therapy of Sporadic and NF2-related vestibular schwannoma","volume":"12","author":"Yao","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.otc.2021.05.004_bib16","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1200\/JCO.2016.71.7199","article-title":"CNS tumors in neurofibromatosis","volume":"35","author":"Campian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.otc.2021.05.004_bib17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"Buerki","year":"2018","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.004_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/neuros\/nyy121","article-title":"Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease","volume":"83","author":"Kerr","year":"2018","journal-title":"Neurosurgery"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/s-2007-1016956","article-title":"Recurrence and outcome in skull base meningiomas: do they differ from other intracranial meningiomas?","volume":"18","author":"Nanda","year":"2008","journal-title":"Skull Base"},{"issue":"5","key":"10.1016\/j.otc.2021.05.004_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tcb.2007.03.006","article-title":"Shedding light on Merlin's wizardry","volume":"17","author":"Okada","year":"2007","journal-title":"Trends Cell Biol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ncb1339","article-title":"The tumour-suppressor genes NF2\/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis","volume":"8","author":"Hamaratoglu","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.otc.2021.05.004_bib22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1593\/neo.08642","article-title":"The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP","volume":"10","author":"Striedinger","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.otc.2021.05.004_bib23","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.wneu.2018.06.010","article-title":"Deregulation of the hippo pathway promotes tumor cell proliferation through yap activity in human sporadic vestibular schwannoma","volume":"117","author":"Zhao","year":"2018","journal-title":"World Neurosurg"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nec.2015.11.002","article-title":"Medical management of meningiomas: current status, failed treatments, and promising horizons","volume":"27","author":"Karsy","year":"2016","journal-title":"Neurosurg Clin N Am"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib25","first-page":"116","article-title":"Von Hippel-Lindau disease","volume":"5","author":"Findeis-Hosey","year":"2016","journal-title":"J\u00a0Pediatr Genet"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib26","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.rcl.2015.12.004","article-title":"von Hippel-Lindau disease: review of genetics and imaging","volume":"54","author":"Shanbhogue","year":"2016","journal-title":"Radiol Clin North Am"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib27","first-page":"503","article-title":"Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment","volume":"102","author":"Kim","year":"2005","journal-title":"J\u00a0Neurosurg"},{"issue":"12","key":"10.1016\/j.otc.2021.05.004_bib28","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1158\/1078-0432.CCR-17-0547","article-title":"Von Hippel-Lindau and hereditary pheochromocytoma\/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood","volume":"23","author":"Rednam","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/joim.12869","article-title":"Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma","volume":"285","author":"Muth","year":"2019","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.otc.2021.05.004_bib30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2016.01.022","article-title":"Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era","volume":"100","author":"Pillai","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.nec.2015.03.012","article-title":"Chordomas: a review","volume":"26","author":"George","year":"2015","journal-title":"Neurosurg Clin N Am"},{"issue":"8","key":"10.1016\/j.otc.2021.05.004_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/neuonc\/noq003","article-title":"Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas","volume":"12","author":"Tamborini","year":"2010","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.otc.2021.05.004_bib33","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1158\/1535-7163.MCT-17-0597","article-title":"Path toward precision oncology: review of targeted therapy studies and tools to aid in defining \"actionability\" of a molecular lesion and patient management support","volume":"16","author":"Chae","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.otc.2021.05.004_bib34","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1172\/JCI21507","article-title":"Persistence--luck--Avastin","volume":"113","author":"Goodman","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"5","key":"10.1016\/j.otc.2021.05.004_bib35","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0038-1676628","article-title":"Long-term effects of bevacizumab on vestibular schwannoma volume in neurofibromatosis type 2 patients","volume":"80","author":"Killeen","year":"2019","journal-title":"J\u00a0Neurol Surg B Skull Base"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.otc.2021.05.004_bib37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"issue":"5","key":"10.1016\/j.otc.2021.05.004_bib38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuchi.2016.09.004","article-title":"Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports","volume":"64","author":"Goutagny","year":"2018","journal-title":"Neurochirurgie"},{"issue":"12","key":"10.1016\/j.otc.2021.05.004_bib39","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"14","key":"10.1016\/j.otc.2021.05.004_bib40","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib41","first-page":"281","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"12","key":"10.1016\/j.otc.2021.05.004_bib42","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","article-title":"Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"272","author":"Farschtschi","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","article-title":"Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2","volume":"124","author":"Hochart","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib44","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0194599818809085","article-title":"Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities","volume":"160","author":"Sverak","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"35","key":"10.1016\/j.otc.2021.05.004_bib45","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.otc.2021.05.004_bib46","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14737175.2016.1184087","article-title":"Systemic therapy for recurrent meningioma","volume":"16","author":"Le Rhun","year":"2016","journal-title":"Expert Rev Neurother"},{"issue":"Suppl 5","key":"10.1016\/j.otc.2021.05.004_bib47","doi-asserted-by":"crossref","first-page":"v130","DOI":"10.1093\/neuonc\/nov220.04","article-title":"MNGO-04: phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma","volume":"17","author":"Grimm","year":"2015","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.otc.2021.05.004_bib48","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3109\/0284186X.2013.878472","article-title":"Durable stabilization of three chordoma cases by bevacizumab and erlotinib","volume":"53","author":"Asklund","year":"2014","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"issue":"11","key":"10.1016\/j.otc.2021.05.004_bib50","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"15","key":"10.1016\/j.otc.2021.05.004_bib51","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-b enzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J\u00a0Med Chem"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-014-1358-9","article-title":"A\u00a0phase II trial of PTK787\/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas","volume":"117","author":"Raizer","year":"2014","journal-title":"J\u00a0Neurooncol"},{"issue":"8","key":"10.1016\/j.otc.2021.05.004_bib53","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.clinthera.2008.08.008","article-title":"Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases","volume":"30","author":"Medina","year":"2008","journal-title":"Clin Ther"},{"issue":"13","key":"10.1016\/j.otc.2021.05.004_bib54","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1517\/14656566.8.13.2189","article-title":"Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer","volume":"8","author":"Mukherjee","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.otc.2021.05.004_bib55","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MAO.0b013e31821f7d88","article-title":"ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas","volume":"32","author":"Ahmad","year":"2011","journal-title":"Otol Neurotol"},{"issue":"9","key":"10.1016\/j.otc.2021.05.004_bib56","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.otc.2021.05.004_bib57","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.otc.2021.05.004_bib58","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/annonc\/mdt117","article-title":"Phase II study on lapatinib in advanced EGFR-positive chordoma","volume":"24","author":"Stacchiotti","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.otc.2021.05.004_bib59","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.189601","article-title":"The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44","volume":"15","author":"Morrison","year":"2001","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib60","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3892\/ijo.2013.1798","article-title":"Microarray analysis of gene expression in vestibular schwannomas reveals SPP1\/MET signaling pathway and androgen receptor deregulation","volume":"42","author":"Torres-Martin","year":"2013","journal-title":"Int J Oncol"},{"issue":"34","key":"10.1016\/j.otc.2021.05.004_bib61","doi-asserted-by":"crossref","first-page":"54515","DOI":"10.18632\/oncotarget.10248","article-title":"Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1","volume":"7","author":"Troutman","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.otc.2021.05.004_bib62","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J\u00a0Med Chem"},{"issue":"18","key":"10.1016\/j.otc.2021.05.004_bib63","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","article-title":"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.otc.2021.05.004_bib64","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.otc.2021.05.004_bib65","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/JTO.0b013e3181b62572","article-title":"Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib","volume":"4","author":"Katayama","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00280-007-0616-3","article-title":"The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates","volume":"62","author":"Meany","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.otc.2021.05.004_bib67","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.otc.2021.05.004_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejca.2017.03.037","article-title":"Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF\/GETO) and the Association des Neuro-Oncologues d'Expression Francaise (ANOCEF)","volume":"79","author":"Lebellec","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib69","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J\u00a0Neurooncol"},{"issue":"12","key":"10.1016\/j.otc.2021.05.004_bib70","first-page":"572","article-title":"Effectiveness of cetuximab\/gefitinib in the therapy of a sacral chordoma","volume":"29","author":"Hof","year":"2006","journal-title":"Onkologie"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/02841860802266672","article-title":"Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib","volume":"48","author":"Linden","year":"2009","journal-title":"Acta Oncol"},{"issue":"6","key":"10.1016\/j.otc.2021.05.004_bib72","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/neuonc\/not242","article-title":"mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma","volume":"16","author":"Giovannini","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib74","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J\u00a0Neurooncol"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11060-017-2447-3","article-title":"A\u00a04-year phase II study of everolimus in NF2 patients with growing vestibular schwannomas","volume":"133","author":"Goutagny","year":"2017","journal-title":"J\u00a0Neurooncol"},{"issue":"Suppl 5","key":"10.1016\/j.otc.2021.05.004_bib77","doi-asserted-by":"crossref","first-page":"v15","DOI":"10.1093\/neuonc\/nou237.30","article-title":"AT-30: effects of everolimus on meningioma growth in patients with neurofibromatosis type 2","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib78","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.otc.2021.05.004_bib79","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/annonc\/mdp210","article-title":"Response to imatinib plus sirolimus in advanced chordoma","volume":"20","author":"Stacchiotti","year":"2009","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.otc.2021.05.004_bib80","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.otc.2021.05.004_bib81","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003495-199345020-00003","article-title":"Interferon-alpha in malignant and viral diseases. A Review","volume":"45","author":"Dorr","year":"1993","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.otc.2021.05.004_bib82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/cns.13.17","article-title":"IFN-alpha for recurrent surgery- and radiation-refractory high-grade meningioma: a retrospective case series","volume":"2","author":"Chamberlain","year":"2013","journal-title":"CNS Oncol"},{"issue":"8","key":"10.1016\/j.otc.2021.05.004_bib83","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.otc.2021.05.004_bib84","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules22101551","article-title":"Current development status of MEK inhibitors","volume":"22","author":"Cheng","year":"2017","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.otc.2021.05.004_bib85","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/neuonc\/noz002","article-title":"Preclinical assessment of MEK1\/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development","volume":"21","author":"Fuse","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.otc.2021.05.004_bib86","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1038\/s41598-020-60156-6","article-title":"Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma","volume":"10","author":"Sagers","year":"2020","journal-title":"Sci Rep"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:53:51Z","timestamp":1758466431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666521000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":86,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0030666521000840"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2021.05.004","relation":{},"ISSN":["0030-6665"],"issn-type":[{"value":"0030-6665","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological Treatments of Neurofibromatosis Type 2 and Other Skull Base Disorders","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2021.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}